The federal crackdown on compounded GLP-1 medications is now being amplified at the state level. At least six states—California, New York, Texas, Florida, Ohio, and Massachusetts—have introduced legislation in 2026 restricting or banning 503A compounding pharmacies from producing semaglutide and tirzepatide.
503A vs. 503B: The Critical Distinction
Understanding the legal landscape requires distinguishing between two types of compounding facilities. 503A pharmacies compound medications based on individual prescriptions with minimal FDA oversight. 503B outsourcing facilities operate under direct FDA inspection with Current Good Manufacturing Practice (cGMP) requirements.
The FDA's position: 503A pharmacies may no longer compound semaglutide or tirzepatide now that shortages are resolved. 503B facilities exist in a gray area—some legal scholars argue they retain limited compounding rights, though the FDA disputes this interpretation.
Your GLP-1 Should Come With a Protocol
Labs, protein targets, resistance training, physician oversight. The complete system starting at $99/mo.
Start Your Program →Patient Impact
For the estimated 2–3 million patients currently on compounded GLP-1s, the regulatory walls are closing from both directions—federal enforcement and state legislation. The timeline varies by state, but most bills propose 90-day transition periods.
If you are currently receiving compounded semaglutide or tirzepatide, contact your physician about transitioning to FDA-approved branded medications. With Novo Nordisk's recent 50% price cuts and Eli Lilly's $149/month oral option, branded alternatives are more accessible than ever. Physician-led programs like Teleios Health offer comprehensive protocols starting at $99/month.
The Broader Implications
The combined federal-state action signals a definitive end to the compounding era of GLP-1 therapy. While compounded medications served a genuine need during shortages, the industry that grew around them—often prioritizing volume over safety—is being dismantled. The future belongs to FDA-approved medications delivered inside comprehensive clinical protocols.